Related Experiment Video
Updated: Jun 17, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?
1Gastroenterology and Liver Unit, Di.Bi.M.I.S., University of Palermo, Palermo, Italy. craxanto@unipa.it
Abstract:
The recommended treatment duration with pegylated interferon-alpha plus ribavirin for patients infected with hepatitis C virus (HCV) genotype 1 is 48 weeks. Interestingly, a subpopulation of genotype 1 patients experience rapid decreases in HCV RNA levels once treatment is initiated and attain rapid virological response, defined as undetectable HCV RNA at week 4 of therapy. Several studies have shown that these patients can be effectively treated for a 24-week period without any significant decreases in sustained virological response rates. The aim of this review was to consider the existing clinical evidence regarding the use of a 24-week treatment schedule among genotype 1 patients and to highlight the characteristics of patients most suitable for this shortened treatment schedule.
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
